Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EED | O75530 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178879 | 0.91 | MEN1 (0.61) | HTR2CMEN1KMT2AEEDDDB1 | |
| SCHEMBL31494212 | 0.91 | MEN1 (0.61) | HTR2CMEN1KMT2AEEDDDB1 | |
| SCHEMBL2808985 | 0.91 | MEN1 (0.61) | HTR2CMEN1KMT2AEEDDDB1 | |
| SCHEMBL3154247 | 0.87 | HTR2C (0.56) | HTR2CMEN1KMT2ADDB1CRBN | |
| SCHEMBL13801054 | 0.85 | HTR2C (0.55) | HTR2CMEN1KMT2ADDB1CRBN | |
| SCHEMBL1636847 | 0.84 | HTR2C (0.56) | HTR2CMEN1KMT2AEEDADRB1 | |
| SCHEMBL1637555 | 0.84 | HTR2C (0.56) | HTR2CMEN1KMT2AEEDADRB1 | |
| SCHEMBL1637389 | 0.84 | HTR2C (0.56) | HTR2CMEN1KMT2AEEDADRB1 | |
| SCHEMBL12536772 | 0.82 | MEN1 (0.50) | HTR2CMEN1KMT2AADRB1GID4 | |
| SCHEMBL2863498 | 0.78 | HTR2C (0.69) | HTR2CEED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| WO-2010015972-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | HTR2C 190/4885MEN1 159/4885KMT2A 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.